Professor of Therapeutic Radiology; Vice Chair for Clinical Research, Therapeutic Radiology; Director of the Clinical Trials Office, Yale Cancer Center; Associate Cancer Center Director, Clinical Sciences; Disease Aligned Research Team Leader, Therapeutic Radiology, Yale Cancer Center; Associate Director, Residency Training Program, Therapeutic Radiology
Developmental Research Program
The primary goal of the Developmental Research Program (DRP) of the Yale SPORE in Head & Neck Cancer (YHN-SPORE) is to identify and fund innovative pilot projects that possess translational potential to make an impact in the field of head & neck cancer in the areas of risk assessment, early detection, biomarkers for prognosis and therapy prediction, mechanisms of carcinogenesis/tumorigenesis, novel therapeutic targets, development of novel therapeutics, and novel treatment approaches.
Investigators of funded developmental research projects are strongly encouraged to collaborate with other investigators within and outside of the YHN-SPORE institutions, including other SPORE communities.
The purpose is to provide each funded DRP project with the potential to evolve into independent full SPORE projects or equivalent-scale study proposals.
Ultimately, along with the main YHN-SPORE projects, the outcome from this program will contribute to the reduction of head & neck cancer morbidity and mortality in the US and worldwide.
Previous Developmental Research Awardees
- 2021 Developmental Research Awardees
- Immunocompetent Syngeneic Mouse Models for Investigating Tumor Immune Microenvironment Dynamics (Antonio Amelio, University of North Carolina)
- Defined genetic alterations as a biomarker predicting therapy response and prognosis in HPV-associated head and neck cancer (Natalia Isaeva, University of North Carolina)
- Regulation of autophagy to optimize AURKA inhibition-mediated therapeutics in head and neck cancer (Jong Woo Lee)
- Discovery of New Biomarkers Associated with Immunotherapy Treatment in HNSCC (David Rimm, Yale University)
- Investigating Genetic Ancestry and Therapeutic Response Among African American Oral Cavity and Laryngeal Cancer Patients (Camille Ragin, Fox Chase Cancer Center)
- Understanding how HNSCC-associated ERK2 mutations sensitize to EGFR inhibition (Benjamin Turk, Yale University)
Developmental Research Program Directors
Professor of Medicine (Medical Oncology); Interim Associate Cancer Center Director, Diversity, Equity, and Inclusion; Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Leader, Developmental Therapeutics, Yale Cancer Center
Professor of Pharmacology and of Molecular Biophysics and Biochemistry; Co-Leader, Developmental Therapeutics, Yale Cancer Center; Co-Director Therapeutics/Chemotherapy Program